The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $2.94

Today's change+0.07 +2.44%
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $2.94

Today's change+0.07 +2.44%
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc up sharply

Orexigen Therapeutics Inc closed up sharply Thursday, rallying (U.S.)$0.07 or 2.44% to (U.S.)$2.94. Shares have lost 4.55% over the last five days, but have gained 68.97% over the last year to date. This security has underperformed the S&P 500 by 46.86% during the last year.

Key company metrics

  • Open(U.S.) $2.94
  • Previous close(U.S.) $2.87
  • High(U.S.) $2.94
  • Low(U.S.) $2.85
  • Bid / Ask(U.S.) $2.57 / (U.S.) $5.00
  • YTD % change+68.97%
  • Volume44,476
  • Average volume (10-day)115,449
  • Average volume (1-month)173,295
  • Average volume (3-month)368,406
  • 52-week range(U.S.) $1.65 to (U.S.) $6.49
  • Beta2.89
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.78
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-149.02%

Although this company's net profit margin is negative, it is above the industry average and implies that Orexigen Therapeutics Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.06%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue191478
Total other revenue--------
Total revenue191478
Gross profit131056
Total cost of revenue6422
Total operating expense6139-3641
Selling / general / administrative55423525
Research & development87514
Depreciation / amortization221--
Interest expense (income), net operating--------
Unusual expense (income)-11-161--
Other operating expenses, total--0-80--
Operating income-42-2543-33
Interest income (expense), net non-operating-1-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-69-2448-25
Income after tax-69-2548-25
Income tax, total--0----
Net income-69-2548-25
Total adjustments to net income--------
Net income before extra. items-69-2548-25
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-69-2548-25
Inc. avail. to common incl. extra. items-69-2548-25
Diluted net income-69-2548-25
Dilution adjustment--------
Diluted weighted average shares15153715
Diluted EPS excluding extraordinary itemsvalue per share-4.67-1.691.30-1.73
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-5.40-2.411.33-1.73